eVLP‐Mediated Cas9 Delivery for Preventing IBMIR in Islet Transplantation
Open Access
Abstract
Islet transplantation is a promising strategy for effective β‐cell replacement in patients with type 1 diabetes. However, its success is hindered significantly by instant blood‐mediated inflammatory reaction (IBMIR), which leads to rapid graft loss. IBMIR is triggered when the transplanted islets come in contact with blood, activating the coagulation cascade, complement pathways, and innate immune responses. Tissue factor (TF), abundantly expressed on the islet surface, initiates the coagulation cascade, leading to thrombin formation, platelet activation, and neutrophil infiltration. Plasminogen activator inhibitor‐1 (PAI‐1) plays a critical role in IBMIR by inhibiting fibrinolysis and causing ischemic injury in the graft. TF and PAI‐1 contribute significantly to IBMIR, thus making them critical targets for genetic interventions to prevent IBMIR. In this study, an engineered virus‐like particle (eVLP)–mediated Cas9 nuclease is employed to knock out TF and PAI‐1 genes in rat islets. TF and PAI‐1 expression are effectively downregulated without inducing any off‐target effects or without compromising the viability and functionality of the islets. Streptozotocin‐induced diabetic mice transplanted with TF ‐ and PAI‐1 ‐knockout islets exhibited improved glycemic control and a significant reduction in the plasma levels of thrombin‐antithrombin (TAT) complex and complement component 3a (C3a), indicating the successful inhibition of IBMIR post‐transplantation.Keywords
Funding Information
- National Research Foundation of Korea
- Ministry of Health and Welfare (RS‐2024‐02507183)
- Ministry of Health and Welfare (22A0205L1)
- Ministry of Health and Welfare (23A0205L1)
- Ministry of Health and Welfare (21A0202L1)
- Ministry of Science and ICT, South Korea (21A0202L1)
This publication has 59 references indexed in Scilit:
- Virus-like particle-based delivery of Cas9/guide RNA ribonucleoprotein efficiently edits the brachyury gene and inhibits chordoma growth in vivoDiscover Oncology, 2023
- CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational PerspectiveAdvanced Science, 2023
- Type 1 diabetes and engineering enhanced islet transplantationAdvanced Drug Delivery Reviews, 2022
- Engineered virus-like particles for efficient in vivo delivery of therapeutic proteinsCell, 2022
- Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringCell Reports, 2021
- Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectivesReviews in Endocrine and Metabolic Disorders, 2021
- Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applicationsAdvanced Drug Delivery Reviews, 2020
- Surface modification of pancreatic islets using heparin-DOPA conjugate and anti-CD154 mAb for the prolonged survival of intrahepatic transplanted islets in a xenograft modelBiomaterials, 2012
- Surface camouflage of pancreatic islets using 6-arm-PEG-catechol in combined therapy with tacrolimus and anti-CD154 monoclonal antibody for xenotransplantationBiomaterials, 2011
- Interactions between coagulation and complement—their role in inflammationSeminars in Immunopathology, 2011